Preparation of biocompatible copolymeric micelles as a carrier of atorvastatin and rosuvastatin for potential anticancer activity study
Authors:
- 8 May 2018
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 24 (3) , 303-313
Abstract
Statins are widely used for the treatment of hypercholesterolemia. However, their inhibitory action on HMG-CoA reductase also results in the depletion of intermediate biosynthetic products, which importantly contribute to cell proliferation. The aim of the present study was to compare the effects of the individual commercially available statins on investigational breast cancer. Thus, in this study, biodegradable polymeric micelles as carrier of statins were prepared using biodegradable copolymers (PCL–PEG–PCL). These nanoparticles were prepared with two statins (atorvastatin and rosuvastatin) and drug loading, release, kinetic release, and anti-cancer activity of these drugs were studied. The triblock copolymer PCL–PEG–PCL was synthesized by a ring opening polymerization of e-caprolactone in the presence of PEG as the initiator and Sn(oct)2 as the catalyst. The synthesized copolymers and nanoparticles were characterized by FTIR, HNMR, GPC, DLS, and AFM analyses. The drug loading and release of drugs were studied by UV–Vis. Additionally, MTT assays on HFF-2 cell lines were performed for determination of biocompatibility of micelles. Finally, the anticancer activity of micelles was studied on MCF-7 breast cancer cell lines. The results showed that the average diameter of nanoparticles was less than 45 nm. The loading capacity of atorvastatin and rosuvastatin was 20.0 ± 1.01% and 13.21 ± 1.18%, respectively, and encapsulation efficiency of atorvastatin and rosuvastatin was 88.19 ± 1.11% and 69.32 ± 0.23%, respectively. The results showed strong and dose-dependent inhibition of cell (MCF-7line) growth by the nanoparticles compared with statins. The result of cell viability assay on the MCF-7 cell line verified that the bare nanoparticles showed little inherent cytotoxicity whereas the statins-loaded nanoparticles were cytotoxic.Keywords
Funding Information
- Zanjan University of Medical Sciences (A-12-430-7)
This publication has 24 references indexed in Scilit:
- Nanoethosomes for Dermal Delivery of LidocaineAdvanced Pharmaceutical Bulletin, 2015
- Nonionic surfactant-based vesicular system for transdermal drug deliveryDrug Delivery, 2014
- Preparation of optimized Naproxen nano liposomes using response surface methodologyJournal of Pharmaceutical Investigation, 2013
- Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticlesNanomedicine: Nanotechnology, Biology and Medicine, 2006
- Chemical, pharmacokinetic and pharmacodynamic properties of statins: an updateFundamental & Clinical Pharmacology, 2004
- Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cellsMenopause, 2003
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasisGastroenterology, 2002
- A Comparison of the Effect of the 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors Simvastatin, Lovastatin and Pravastatin on Leukaemic and Normal Bone Marrow ProgenitorsLeukemia & Lymphoma, 1997
- Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatinCancer Letters, 1996
- Inhibition of pancreatic adenocarcinoma cell growth by lovastatinGastroenterology, 1992